Envisia Therapeutics Inc.
Betting implants can best eyedrops in glaucoma
This article was originally published in Start Up
Envisia Therapeutics Inc. is betting that a proprietary method of engineering micro- and nanoparticles of precise size, shape, and chemistry will enable it to develop drugs for direct delivery to various compartments of the eye. The start-up, formed in November 2013 as a spin-out from Liquidia Technologies Inc., has licensed rights to the parent company's Particle Replication in Non-wetting Templates (PRINT) technology to create new ocular therapies.